Mitoxantrone for multiple sclerosis in clinical practice.
Patients with worsening relapsing-remitting multiple sclerosis (MS), secondary progressive MS, and progressive relapsing MS are potential candidates for treatment with mitoxantrone. Early identification of these patients is essential because there is emerging evidence that early and aggressive treatment might delay or limit long-term disability. Treatment with mitoxantrone is associated with certain adverse events, such as cardiotoxicity. However, the possible benefits of treatment (e.g., reduction in disease progression) outweigh the risks for patients with aggressive or worsening disease. With the selection of appropriate patients and careful monitoring for adverse events, mitoxantrone can be safely administered.
Rizvi
Syed A
SA
Department of Clinical Neurosciences, Brown University, 2 Dudley Street, Suite 555, Providence, Rhode Island 02905, USA. srizvi@lifespan.org
Zwibel
Howard
H
Fox
Edward J
EJ
D000075202:Contraindications; D004334:Drug Administration Schedule; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008942:Mitoxantrone / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000503:physiopathology; D010353:Patient Education as Topic; D018579:Patient Selection
D007166:Immunosuppressive Agents; D008942:Mitoxantrone